TY - JOUR
T1 - Combined analysis of the effect of treatment with ursodeoxycholic acid on histologic progression in primary biliary cirrhosis
AU - Poupon, Renée Eugénie
AU - Lindor, Keith D.
AU - Parés, Albert
AU - Chazouillères, Olivier
AU - Poupon, Raoul
AU - Heathcote, E. Jenny
PY - 2003/7/1
Y1 - 2003/7/1
N2 - Background/Aims: This study aimed at evaluating the effect of ursodeoxycholic acid (UDCA) treatment on histologic progression in primary biliary cirrhosis (PBC). Methods: Using combined individual histologic findings from four clinical trials, we selected the patients in whom paired liver-biopsy specimens were available with a time interval of about 36 months between biopsies. A total of 367 patients were selected (UDCA: 200 vs. placebo: 167). Results: Overall, there was no significant difference in the progression of the histologic stage between the two groups. By contrast, in the subgroup of patients with initial stages I-II (n = 177) there was a significant decrease in the histologic stage progression in the UDCA group relative to the placebo group (P < 0.03). Overall, there was a significant delay in the progression of periportal necroinflammatory lesions (P = 0.03), and an improvement in the degree of ductular proliferation (P = 0.02) in the UDCA group compared with the placebo group. There was no significant difference in the progression of other specific lesions. Conclusions: A 2-year UDCA treatment reduces periportal necroinflammation and improves ductular proliferation, and when initiated at the earlier stages I-II of the disease also delays the progression of histologic stage. These data support the early initiation of the drug to prevent these histologic features of PBC.
AB - Background/Aims: This study aimed at evaluating the effect of ursodeoxycholic acid (UDCA) treatment on histologic progression in primary biliary cirrhosis (PBC). Methods: Using combined individual histologic findings from four clinical trials, we selected the patients in whom paired liver-biopsy specimens were available with a time interval of about 36 months between biopsies. A total of 367 patients were selected (UDCA: 200 vs. placebo: 167). Results: Overall, there was no significant difference in the progression of the histologic stage between the two groups. By contrast, in the subgroup of patients with initial stages I-II (n = 177) there was a significant decrease in the histologic stage progression in the UDCA group relative to the placebo group (P < 0.03). Overall, there was a significant delay in the progression of periportal necroinflammatory lesions (P = 0.03), and an improvement in the degree of ductular proliferation (P = 0.02) in the UDCA group compared with the placebo group. There was no significant difference in the progression of other specific lesions. Conclusions: A 2-year UDCA treatment reduces periportal necroinflammation and improves ductular proliferation, and when initiated at the earlier stages I-II of the disease also delays the progression of histologic stage. These data support the early initiation of the drug to prevent these histologic features of PBC.
KW - Histologic features
KW - Histologic progression
KW - Liver fibrosis
KW - Medical treatment
KW - Primary biliary cirrhosis
UR - http://www.scopus.com/inward/record.url?scp=0038170271&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0038170271&partnerID=8YFLogxK
U2 - 10.1016/S0168-8278(03)00192-2
DO - 10.1016/S0168-8278(03)00192-2
M3 - Article
C2 - 12821038
AN - SCOPUS:0038170271
SN - 0168-8278
VL - 39
SP - 12
EP - 16
JO - Journal of Hepatology
JF - Journal of Hepatology
IS - 1
ER -